---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066939"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:42:15.966818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q1 net loss $96.8M; cash $1.3B; paltusotine PDUFA Sept 25, 2025

## Summary
- Net loss of $96.8M for Q1 2025 vs. $66.9M in Q1 2024, driven by higher R&D and SG&A costs.
- Revenue $0.4M, down from $0.6M; primarily from Sanwa Kagaku licensing agreement.
- Cash, equivalents, and investments $1.3B, expected to fund operations into 2029.
- Paltusotine NDA under FDA review with PDUFA target action date Sept 25, 2025.
- Phase 3 CALM-CAH study of atumelnant in CAH to begin H2 2025; R&D Day June 26.

## SEC filing metadata
- accession: 0000950170-25-066939
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025066939/0000950170-25-066939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025066939/crnx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066939
- JSON: https://secwatch.observer/filing/0000950170-25-066939.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.